共 34 条
Vitamin D Decreases Serum VEGF Correlating with Clinical Improvement in Vitamin D-Deficient Women with PCOS: A Randomized Placebo-Controlled Trial
被引:39
作者:
Irani, Mohamad
[1
]
Seifer, David B.
[2
]
Grazi, Richard V.
[3
]
Irani, Sara
[4
,5
,6
]
Rosenwaks, Zev
[1
]
Tal, Reshef
[7
]
机构:
[1] Weill Cornell Med, Ronald O Perelman & Claudia Cohen Ctr Reprod Med, New York, NY 10021 USA
[2] Geisel Sch Med Dartmouth, Dartmouth Hitchcock Med Ctr, Lebanon, NH 03756 USA
[3] Maimonides Hosp, Genesis Fertil & Reprod Med, Brooklyn, NY 11204 USA
[4] State Univ New York SUNY Downstate Med Ctr, Sch Grad Studies, Mol & Cell Biol Program, Brooklyn, NY 11203 USA
[5] State Univ New York SUNY Downstate Med Ctr, Dept Cell Biol, Brooklyn, NY 11203 USA
[6] State Univ New York SUNY Downstate Med Ctr, Dept Pediat, Brooklyn, NY 11203 USA
[7] Yale Univ, Div Reprod Endocrinol & Infertil, Dept Obstet Gynecol & Reprod Sci, Sch Med, New Haven, CT 06520 USA
来源:
NUTRIENTS
|
2017年
/
9卷
/
04期
关键词:
vitamin D;
vascular endothelial growth factor;
VEGF;
polycystic ovary syndrome;
PCOS;
ENDOTHELIAL GROWTH-FACTOR;
POLYCYSTIC-OVARY-SYNDROME;
STROMAL BLOOD-FLOW;
INSULIN-RESISTANCE;
PATHOGENESIS;
EXPRESSION;
THERAPY;
GLUCOSE;
MARKER;
IMPACT;
D O I:
10.3390/nu9040334
中图分类号:
R15 [营养卫生、食品卫生];
TS201 [基础科学];
学科分类号:
100403 ;
摘要:
Vascular endothelial growth factor (VEGF) has been suggested to play a role in the pathophysiology of polycystic ovary syndrome (PCOS) and may contribute to increased risk of ovarian hyperstimulation syndrome (OHSS) in affected individuals. Vitamin D (VitD) supplementation improves multiple clinical parameters in VitD-deficient women with PCOS and decreases VEGF levels in several other pathologic conditions. Unveiling the basic mechanisms underlying the beneficial effects of vitamin D on PCOS may enhance our understanding of the pathophysiology of this syndrome. It may also suggest a new treatment for PCOS that can improve it through the same mechanism as vitamin D and can be given regardless of vitamin D levels. Therefore, we aimed to explore the effect of VitD supplementation on serum VEGF levels and assess whether changes in VEGF correlate with an improvement in characteristic clinical abnormalities of PCOS. This is a randomized placebo-controlled trial conducted between October 2013 and March 2015. Sixty-eight VitD-deficient women with PCOS were recruited. Women received either 50,000 IU of oral VitD3 or placebo once weekly for 8 weeks. There was a significant decrease in serum VEGF levels (1106.4 +/- 36.5 to 965.3 +/- 42.7 pg.mL(-1); p < 0.001) in the VitD group. Previously reported findings of this trial demonstrated a significant decrease in the intermenstrual intervals, Ferriman-Gallwey hirsutism score, and triglycerides following VitD supplementation. Interestingly, D VEGF was positively correlated with D triglycerides (R-2 = 0.22; p = 0.02) following VitD supplementation. In conclusion, VitD replacement significantly decreases serum VEGF levels correlating with a decrease in triglycerides in women with PCOS. This is a novel molecular explanation for the beneficial effects of VitD treatment. It also suggests the need to investigate a potential role of VitD treatment in reducing the incidence or severity of OHSS in VitD-deficient women with PCOS.
引用
收藏
页数:8
相关论文